Selection criteria for genetic assessment of patients with familial melanoma

Sancy A. Leachman, John Carucci, Wendy Kohlmann, Kimberly C. Banks, Maryam M. Asgari, Wilma Bergman, Giovanna Bianchi-Scarrà, Teresa Brentnall, Brigitte Bressac-de Paillerets, William Bruno, Clara N Curiel, Femke A. de Snoo, Tadeusz Debniak, Marie France Demierre, David Elder, Alisa M. Goldstein, Jane Grant-Kels, Allan C. Halpern, Christian Ingvar, Richard F. Kefford & 14 others Julie Lang, Rona M. MacKie, Graham J. Mann, Kurt Mueller, Julia Newton-Bishop, Håkan Olsson, Gloria M. Petersen, Susana Puig, Darrell Rigel, Susan M. Swetter, Margaret A. Tucker, Emanuel Yakobson, John A. Zitelli, Hensin Tsao

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Approximately 5% to 10% of melanoma may be hereditary in nature, and about 2% of melanoma can be specifically attributed to pathogenic germline mutations in cyclin-dependent kinase inhibitor 2A (CDKN2A). To appropriately identify the small proportion of patients who benefit most from referral to a genetics specialist for consideration of genetic testing for CDKN2A, we have reviewed available published studies of CDKN2A mutation analysis in cohorts with invasive, cutaneous melanoma and found variability in the rate of CDKN2A mutations based on geography, ethnicity, and the type of study and eligibility criteria used. Except in regions of high melanoma incidence, such as Australia, we found higher rates of CDKN2A positivity in individuals with 3 or more primary invasive melanomas and/or families with at least one invasive melanoma and two or more other diagnoses of invasive melanoma and/or pancreatic cancer among first- or second-degree relatives on the same side of the family. The work summarized in this review should help identify individuals who are appropriate candidates for referral for genetic consultation and possible testing.

Original languageEnglish (US)
JournalJournal of the American Academy of Dermatology
Volume61
Issue number4
DOIs
StatePublished - Oct 2009

Fingerprint

Cyclin-Dependent Kinase Inhibitor p16
Patient Selection
Melanoma
Referral and Consultation
Mutation
Geography
Germ-Line Mutation
Genetic Testing
Cutaneous Malignant Melanoma
Pancreatic Neoplasms
Cohort Studies
Skin
Incidence

Keywords

  • CDKN2A
  • familial
  • genetic counseling
  • genetic testing
  • hereditary
  • melanoma
  • p16

ASJC Scopus subject areas

  • Dermatology

Cite this

Leachman, S. A., Carucci, J., Kohlmann, W., Banks, K. C., Asgari, M. M., Bergman, W., ... Tsao, H. (2009). Selection criteria for genetic assessment of patients with familial melanoma. Journal of the American Academy of Dermatology, 61(4). https://doi.org/10.1016/j.jaad.2009.03.016

Selection criteria for genetic assessment of patients with familial melanoma. / Leachman, Sancy A.; Carucci, John; Kohlmann, Wendy; Banks, Kimberly C.; Asgari, Maryam M.; Bergman, Wilma; Bianchi-Scarrà, Giovanna; Brentnall, Teresa; Bressac-de Paillerets, Brigitte; Bruno, William; Curiel, Clara N; de Snoo, Femke A.; Debniak, Tadeusz; Demierre, Marie France; Elder, David; Goldstein, Alisa M.; Grant-Kels, Jane; Halpern, Allan C.; Ingvar, Christian; Kefford, Richard F.; Lang, Julie; MacKie, Rona M.; Mann, Graham J.; Mueller, Kurt; Newton-Bishop, Julia; Olsson, Håkan; Petersen, Gloria M.; Puig, Susana; Rigel, Darrell; Swetter, Susan M.; Tucker, Margaret A.; Yakobson, Emanuel; Zitelli, John A.; Tsao, Hensin.

In: Journal of the American Academy of Dermatology, Vol. 61, No. 4, 10.2009.

Research output: Contribution to journalArticle

Leachman, SA, Carucci, J, Kohlmann, W, Banks, KC, Asgari, MM, Bergman, W, Bianchi-Scarrà, G, Brentnall, T, Bressac-de Paillerets, B, Bruno, W, Curiel, CN, de Snoo, FA, Debniak, T, Demierre, MF, Elder, D, Goldstein, AM, Grant-Kels, J, Halpern, AC, Ingvar, C, Kefford, RF, Lang, J, MacKie, RM, Mann, GJ, Mueller, K, Newton-Bishop, J, Olsson, H, Petersen, GM, Puig, S, Rigel, D, Swetter, SM, Tucker, MA, Yakobson, E, Zitelli, JA & Tsao, H 2009, 'Selection criteria for genetic assessment of patients with familial melanoma', Journal of the American Academy of Dermatology, vol. 61, no. 4. https://doi.org/10.1016/j.jaad.2009.03.016
Leachman, Sancy A. ; Carucci, John ; Kohlmann, Wendy ; Banks, Kimberly C. ; Asgari, Maryam M. ; Bergman, Wilma ; Bianchi-Scarrà, Giovanna ; Brentnall, Teresa ; Bressac-de Paillerets, Brigitte ; Bruno, William ; Curiel, Clara N ; de Snoo, Femke A. ; Debniak, Tadeusz ; Demierre, Marie France ; Elder, David ; Goldstein, Alisa M. ; Grant-Kels, Jane ; Halpern, Allan C. ; Ingvar, Christian ; Kefford, Richard F. ; Lang, Julie ; MacKie, Rona M. ; Mann, Graham J. ; Mueller, Kurt ; Newton-Bishop, Julia ; Olsson, Håkan ; Petersen, Gloria M. ; Puig, Susana ; Rigel, Darrell ; Swetter, Susan M. ; Tucker, Margaret A. ; Yakobson, Emanuel ; Zitelli, John A. ; Tsao, Hensin. / Selection criteria for genetic assessment of patients with familial melanoma. In: Journal of the American Academy of Dermatology. 2009 ; Vol. 61, No. 4.
@article{8021189d14ac4a369e0e26abf347ac03,
title = "Selection criteria for genetic assessment of patients with familial melanoma",
abstract = "Approximately 5{\%} to 10{\%} of melanoma may be hereditary in nature, and about 2{\%} of melanoma can be specifically attributed to pathogenic germline mutations in cyclin-dependent kinase inhibitor 2A (CDKN2A). To appropriately identify the small proportion of patients who benefit most from referral to a genetics specialist for consideration of genetic testing for CDKN2A, we have reviewed available published studies of CDKN2A mutation analysis in cohorts with invasive, cutaneous melanoma and found variability in the rate of CDKN2A mutations based on geography, ethnicity, and the type of study and eligibility criteria used. Except in regions of high melanoma incidence, such as Australia, we found higher rates of CDKN2A positivity in individuals with 3 or more primary invasive melanomas and/or families with at least one invasive melanoma and two or more other diagnoses of invasive melanoma and/or pancreatic cancer among first- or second-degree relatives on the same side of the family. The work summarized in this review should help identify individuals who are appropriate candidates for referral for genetic consultation and possible testing.",
keywords = "CDKN2A, familial, genetic counseling, genetic testing, hereditary, melanoma, p16",
author = "Leachman, {Sancy A.} and John Carucci and Wendy Kohlmann and Banks, {Kimberly C.} and Asgari, {Maryam M.} and Wilma Bergman and Giovanna Bianchi-Scarr{\`a} and Teresa Brentnall and {Bressac-de Paillerets}, Brigitte and William Bruno and Curiel, {Clara N} and {de Snoo}, {Femke A.} and Tadeusz Debniak and Demierre, {Marie France} and David Elder and Goldstein, {Alisa M.} and Jane Grant-Kels and Halpern, {Allan C.} and Christian Ingvar and Kefford, {Richard F.} and Julie Lang and MacKie, {Rona M.} and Mann, {Graham J.} and Kurt Mueller and Julia Newton-Bishop and H{\aa}kan Olsson and Petersen, {Gloria M.} and Susana Puig and Darrell Rigel and Swetter, {Susan M.} and Tucker, {Margaret A.} and Emanuel Yakobson and Zitelli, {John A.} and Hensin Tsao",
year = "2009",
month = "10",
doi = "10.1016/j.jaad.2009.03.016",
language = "English (US)",
volume = "61",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Selection criteria for genetic assessment of patients with familial melanoma

AU - Leachman, Sancy A.

AU - Carucci, John

AU - Kohlmann, Wendy

AU - Banks, Kimberly C.

AU - Asgari, Maryam M.

AU - Bergman, Wilma

AU - Bianchi-Scarrà, Giovanna

AU - Brentnall, Teresa

AU - Bressac-de Paillerets, Brigitte

AU - Bruno, William

AU - Curiel, Clara N

AU - de Snoo, Femke A.

AU - Debniak, Tadeusz

AU - Demierre, Marie France

AU - Elder, David

AU - Goldstein, Alisa M.

AU - Grant-Kels, Jane

AU - Halpern, Allan C.

AU - Ingvar, Christian

AU - Kefford, Richard F.

AU - Lang, Julie

AU - MacKie, Rona M.

AU - Mann, Graham J.

AU - Mueller, Kurt

AU - Newton-Bishop, Julia

AU - Olsson, Håkan

AU - Petersen, Gloria M.

AU - Puig, Susana

AU - Rigel, Darrell

AU - Swetter, Susan M.

AU - Tucker, Margaret A.

AU - Yakobson, Emanuel

AU - Zitelli, John A.

AU - Tsao, Hensin

PY - 2009/10

Y1 - 2009/10

N2 - Approximately 5% to 10% of melanoma may be hereditary in nature, and about 2% of melanoma can be specifically attributed to pathogenic germline mutations in cyclin-dependent kinase inhibitor 2A (CDKN2A). To appropriately identify the small proportion of patients who benefit most from referral to a genetics specialist for consideration of genetic testing for CDKN2A, we have reviewed available published studies of CDKN2A mutation analysis in cohorts with invasive, cutaneous melanoma and found variability in the rate of CDKN2A mutations based on geography, ethnicity, and the type of study and eligibility criteria used. Except in regions of high melanoma incidence, such as Australia, we found higher rates of CDKN2A positivity in individuals with 3 or more primary invasive melanomas and/or families with at least one invasive melanoma and two or more other diagnoses of invasive melanoma and/or pancreatic cancer among first- or second-degree relatives on the same side of the family. The work summarized in this review should help identify individuals who are appropriate candidates for referral for genetic consultation and possible testing.

AB - Approximately 5% to 10% of melanoma may be hereditary in nature, and about 2% of melanoma can be specifically attributed to pathogenic germline mutations in cyclin-dependent kinase inhibitor 2A (CDKN2A). To appropriately identify the small proportion of patients who benefit most from referral to a genetics specialist for consideration of genetic testing for CDKN2A, we have reviewed available published studies of CDKN2A mutation analysis in cohorts with invasive, cutaneous melanoma and found variability in the rate of CDKN2A mutations based on geography, ethnicity, and the type of study and eligibility criteria used. Except in regions of high melanoma incidence, such as Australia, we found higher rates of CDKN2A positivity in individuals with 3 or more primary invasive melanomas and/or families with at least one invasive melanoma and two or more other diagnoses of invasive melanoma and/or pancreatic cancer among first- or second-degree relatives on the same side of the family. The work summarized in this review should help identify individuals who are appropriate candidates for referral for genetic consultation and possible testing.

KW - CDKN2A

KW - familial

KW - genetic counseling

KW - genetic testing

KW - hereditary

KW - melanoma

KW - p16

UR - http://www.scopus.com/inward/record.url?scp=70249098475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70249098475&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2009.03.016

DO - 10.1016/j.jaad.2009.03.016

M3 - Article

VL - 61

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 4

ER -